* Proves superior to commonly used medicine methotrexate
* Drug awaiting U.S., European approval decisions
* Likely to compete with J&J's Stelara
NEW York, Oct 11 Abbott Laboratories' (ABT.N)
experimental psoriasis treatment briakinumab, which is awaiting
U.S. and European approval decisions, demonstrated superior
skin clearance rates compared with a commoinly used medicine in
a pivotal late-stage clinical trial, the company said on
In a 52-week study of 317 patients with moderate to severe
psoriasis, the drug was significantly better than methotrexate
in its ability to clear the unsightly, scaly and often painful
skin patches associated with plaque psoriasis -- a disease of
the immune system.
At 24 weeks, 81.8 percent of briakinumab patients achieved
at least a 75 percent skin clearance rate, compared with 39.9
percent for methotrexate.
After 52 weeks, 66.2 percent maintained at least a 75
percent clearance rate on the Abbott drug compared with 23.9
percent for methotrexate, according to data presented on Friday
at the European Association of Dermatology and Venereology
meeting in Gothenburg, Sweden.
Complete skin clearance was seen in 45.5 percent of
briakinumab patients versus 9.2 percent for those who received
Briakinumab is a biotechnology drug that targets proteins
that have been linked to inflammation called IL-12/23.
Abbott filed applications in the third quarter seeking U.S.
and European approval of the drug and will likely receive those
decisions in the second half of next year.
If approved, briakinumab would compete with Johnson &
Johnson's (JNJ.N) Stelara, a new drug from the same class.
The most commonly used biotech medicines for psoriasis,
such as Amgen Inc's (AMGN.O) Enbrel, target a protein known as
tumor necrosis factor.
Briakinumab demonstrated superior skin clearance rates to
Enbrel in earlier Phase III studies that also had data
presented at the meeting in Sweden.
In the newest study versus methotrexate, there were three
cases of cancer reported in the group that received the Abbott
drug. There were also four patients who experienced serious
infections (2.6 percent), compared with three (1.8 percent)
among methotrexate patients, Abbott said.
(Reporting by Bill Berkrot; editing by John Wallace)